{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:45:41Z","timestamp":1740141941081,"version":"3.37.3"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Research Council, Taiwan","doi-asserted-by":"publisher","award":["CRRPG3F0053"],"award-info":[{"award-number":["CRRPG3F0053"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["107-2314-B-182-004-MY3"],"award-info":[{"award-number":["107-2314-B-182-004-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Coronavirus disease 2019, caused by severe acute respiratory\nsyndrome coronavirus 2 (SARS-CoV-2), has wreaked havoc worldwide since December\n2019. Currently, no effective medical treatments have been approved. As the epidemic\ncontinues to spread, SARS-CoV-2 mutants emerge, some of which become more\ninfectious with increasing vaccine resistance. The main route for SARS-CoV-2 to enter\nthe host cells is by binding its spike protein to the host receptor, angiotensin-converting\nenzyme 2 (ACE2). Besides the membrane-bound form of ACE2, the soluble form of\nACE2 (sACE2) can also bind SARS-CoV-2 for viral endocytosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Previously, we found that telbivudine reduced the concentrations of ACE1 in\nblood. Therefore, we speculated that this drug might also reduce the concentrations of\nsACE2.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this retrospective study, serum samples from 39 hepatitis B patients\nreceiving telbivudine were collected and examined for sACE2 concentrations using an\nELISA kit.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>It was found that the serum concentrations of sACE2 were significantly\ndeclined in chronic hepatitis B patients treated with telbivudine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Telbivudine treatment reduced sACE2 concentrations, which could\npotentially reduce the infection risk of SARS-CoV-2.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524022666220510220533","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T07:03:02Z","timestamp":1652252582000},"page":"420-424","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduction of ACE2 Serum Concentrations by Telbivudine in\nChronic Hepatitis B Patients"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-3873","authenticated-orcid":true,"given":"Ya-Hui","family":"Huang","sequence":"first","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Hsiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2174\/156652405774641124","volume":"5","author":"Stadler K.","year":"2005","unstructured":"Stadler K.; Rappuoli R.; SARS: Understanding the virus and development of rational therapy. Curr Mol Med 2005,5(7),677-697","journal-title":"Curr Mol Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","volume":"20","author":"Petersen E.","year":"2020","unstructured":"Petersen E.; Koopmans M.; Go U.; Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020,20(9),e238-e244","journal-title":"Lancet Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.molmed.2020.02.008","volume":"26","author":"Sun J.","year":"2020","unstructured":"Sun J.; He W.T.; Wang L.; COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020,26(5),483-495","journal-title":"Trends Mol Med"},{"key":"ref=4","unstructured":"cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-info.html"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"Scialo F.","year":"2020","unstructured":"Scialo F.; Daniele A.; Amato F.; ACE2: The major cell entry receptor for SARS-CoV-2. Lung 2020,198(6),867-877","journal-title":"Lung"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e016219","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"Guo J.","year":"2020","unstructured":"Guo J.; Huang Z.; Lin L.; Lv J.; Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020,9(7),e016219","journal-title":"J Am Heart Assoc"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11906-014-0420-5","volume":"16","author":"Varagic J.","year":"2014","unstructured":"Varagic J.; Ahmad S.; Nagata S.; Ferrario C.M.; ACE2: Angiotensin II\/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014,16(3),420","journal-title":"Curr Hypertens Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.3390\/ijms22136703","volume":"22","author":"Yalcin H.C.","year":"2021","unstructured":"Yalcin H.C.; Sukumaran V.; Al-Ruweidi M.K.A.A.; Shurbaji S.; Do changes in ACE-2 expression affect SARS-CoV-2 virulence and related complications: A closer look into membrane-bound and soluble forms. Int J Mol Sci 2021,22(13),6703","journal-title":"Int J Mol Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.cell.2021.02.053","volume":"184","author":"Yeung M.L.","year":"2021","unstructured":"Yeung M.L.; Teng J.L.L.; Jia L.; Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 2021,184(8),2212-2228.e12","journal-title":"Cell"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41392-022-00913-3","volume":"7","author":"Ou J.","year":"2022","unstructured":"Ou J.; Zhang Y.; Wang Y.; ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. Signal Transduct Target Ther 2022,7(1),43","journal-title":"Signal Transduct Target Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.clinthera.2007.12.032","volume":"29","author":"Matthews S.J.","year":"2007","unstructured":"Matthews S.J.; Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007,29(12),2635-2653","journal-title":"Clin Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","volume":"146","author":"Gane E.J.","year":"2014","unstructured":"Gane E.J.; Deray G.; Liaw Y.F.; Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014,146(1),138-146.e5","journal-title":"Gastroenterology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"828","DOI":"10.5009\/gnl16484","volume":"11","author":"Park J.","year":"2017","unstructured":"Park J.; Jung K.S.; Lee H.W.; Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis. Gut Liver 2017,11(6),828-834","journal-title":"Gut Liver"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e15074","DOI":"10.5812\/hepatmon.15074","volume":"14","author":"Liang K.H.","year":"2014","unstructured":"Liang K.H.; Chen Y.C.; Hsu C.W.; Chang M.L.; Yeh C.T.; Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon 2014,14(1),e15074","journal-title":"Hepat Mon"},{"key":"ref=15","author":"Aleem A.","year":"2022","unstructured":"Aleem A.; Akbar Samad A.B.; Slenker A.K.;  StatPearls 2022","journal-title":"StatPearls"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1073\/pnas.2016093117","volume":"117","author":"Glasgow A.","year":"2020","unstructured":"Glasgow A.; Glasgow J.; Limonta D.; Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci USA 2020,117(45),28046-28055","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/molecules26010057","volume":"26","author":"Zhu Z.L.","year":"2020","unstructured":"Zhu Z.L.; Qiu X.D.; Wu S.; Blocking effect of demethylzeylasteral on the interaction between human ACE2 protein and SARS-CoV-2 RBD protein discovered using SPR technology. Molecules 2020,26(1),57","journal-title":"Molecules"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s42003-021-01736-8","volume":"4","author":"Karoyan P.","year":"2021","unstructured":"Karoyan P.; Vieillard V.; G&#xF3;mez-Morales L.; Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun Biol 2021,4(1),197","journal-title":"Commun Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"100531","DOI":"10.1016\/j.imu.2021.100531","volume":"23","author":"Rahman M.R.","year":"2021","unstructured":"Rahman M.R.; Banik A.; Chowdhury I.M.; Sajib E.H.; Sarkar S.; Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Inform Med Unlocked 2021,23,100531","journal-title":"Inform Med Unlocked"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/10799893.2020.1772298","volume":"40","author":"Maurya S.K.","year":"2020","unstructured":"Maurya S.K.; Maurya A.K.; Mishra N.; Siddique H.R.; Virtual screening, ADME\/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10\/NSP16 methyltransferase and main protease of SARS CoV-2. J Recept Signal Transduct Res 2020,40(6),605-612","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.3390\/molecules26247458","volume":"26","author":"Elzupir A.O.","year":"2021","unstructured":"Elzupir A.O.; Molecular docking and dynamics investigations for identifying potential inhibitors of the 3-chymotrypsin-like protease of SARS-CoV-2: Repurposing of approved pyrimidonic pharmaceuticals for COVID-19 treatment. Molecules 2021,26(24),7458","journal-title":"Molecules"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/biomedicines9080996","volume":"9","author":"Min J.S.","year":"2021","unstructured":"Min J.S.; Kwon S.; Jin Y.H.; SARS-CoV-2 RdRp inhibitors selected from a cell-based SARS-CoV-2 RdRp activity assay system. Biomedicines 2021,9(8),996","journal-title":"Biomedicines"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524022666220510220533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204566\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524022666220510220533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T06:56:47Z","timestamp":1692428207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204566\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524022666220510220533","relation":{},"ISSN":["1566-5240"],"issn-type":[{"type":"print","value":"1566-5240"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}